Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)
Egypt flag Egypt · Delayed Price · Currency is EGP
4.070
-0.030 (-0.73%)
At close: Apr 2, 2026

EGX:RMDA Income Statement

Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
4,0962,7691,9221,4841,246
Revenue Growth (YoY)
47.94%44.03%29.54%19.06%29.81%
Cost of Revenue
2,1141,4871,018765.28669.61
Gross Profit
1,9821,281904.06718.67576.82
Selling, General & Admin
909.88558.11444.06360.96303.18
Other Operating Expenses
-9.13-27.3-7.34-6.04-0.76
Operating Expenses
1,021558.54458.3376.41302.53
Operating Income
960.05722.93445.76342.26274.29
Interest Expense
-537.97-307.21-191.2-89.07-91.03
Interest & Investment Income
-65.8562.956.7359.97
Currency Exchange Gain (Loss)
-6.1456.2418.6825.65-0.6
Other Non Operating Income (Expenses)
8.16-11.7-8.84-6.99-8.31
EBT Excluding Unusual Items
424.1526.11327.31328.58234.33
Gain (Loss) on Sale of Assets
-0.010.14-0.13-0.72
Pretax Income
424.1526.12327.45328.45233.61
Income Tax Expense
110.89124.3174.2475.5753.52
Earnings From Continuing Operations
313.21401.81253.21252.89180.09
Minority Interest in Earnings
-14.75-14.44-8.35-7.211
Net Income
298.46387.37244.86245.68181.09
Preferred Dividends & Other Adjustments
-23.5321.3616.7614.7
Net Income to Common
298.46363.84223.5228.91166.39
Net Income Growth
-22.95%58.20%-0.33%35.67%61.43%
Shares Outstanding (Basic)
2,2221,9821,9731,9522,015
Shares Outstanding (Diluted)
2,2341,9921,9871,9622,015
Shares Change (YoY)
12.16%0.23%1.27%-2.62%-
EPS (Basic)
0.130.180.110.120.08
EPS (Diluted)
0.130.180.110.120.08
EPS Growth
-26.87%62.40%-3.52%41.22%70.69%
Free Cash Flow
-199.57-371.85-135.54-5.03188.68
Free Cash Flow Per Share
-0.09-0.19-0.07-0.000.09
Dividend Per Share
-0.0400.051--
Dividend Growth
--20.71%---
Gross Margin
48.38%46.28%47.03%48.43%46.28%
Operating Margin
23.44%26.11%23.19%23.06%22.01%
Profit Margin
7.29%13.14%11.63%15.43%13.35%
Free Cash Flow Margin
-4.87%-13.43%-7.05%-0.34%15.14%
EBITDA
1,052802.33514.61403.67316.61
EBITDA Margin
25.69%28.98%26.77%27.20%25.40%
D&A For EBITDA
92.2379.468.8561.4142.31
EBIT
960.05722.93445.76342.26274.29
EBIT Margin
23.44%26.11%23.19%23.06%22.01%
Effective Tax Rate
26.15%23.63%22.67%23.01%22.91%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.